An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

• ClinicalTrials.gov Identifier: NCT00410761
• Recruitment Status: Active, not recruiting
• First Posted: December 13, 2006
• Results First Posted: March 26, 2012
• Last Update Posted: October 2, 2023
• Sponsor: Genzyme, a Sanofi Company
• Information provided by (Responsible Party): Sanofi ( Genzyme, a Sanofi Company )

Tracking Information

• First Submitted Date: December 6, 2006
• First Posted Date: December 13, 2006
• Results First Submitted Date: April 27, 2011
• Results First Posted Date: March 26, 2012
• Last Update Posted Date: October 2, 2023
• Actual Study Start Date: November 30, 2006
• Actual Primary Completion Date: July 31, 2009 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 22, 2012)

Progression-Free Survival(PFS) [ Time Frame: RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent. ]

Median time to progression (months) from randomisation until objective disease progression (determined by RECIST assessments) or death (by any cause in the absence of objective progression) provided death is within 3 months from the last evaluable RECIST assessment. Values here are estimated (from a Weibull model) as the medians were not met.

• Original Primary Outcome Measures (submitted: December 12, 2006): To demonstrate an improvement in progression-free survival with ZD6474 as compared to placebo in subjects with unresectable locally advanced or metastatic medullary thyroid cancer.

Current Secondary Outcome Measures (submitted: February 22, 2012)

• Objective Response Rate (ORR) [ Time Frame: RECIST assessments performed at screening (within 3 weeks before randomisation), then every 12 weeks. For patients with objective response of CR or PR, an additional confirmatory scan was performed ≥4 weeks following the date of first response. ]
  The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) as defined by RECIST criteria. The categories for best objective response are CR, PR, stable disease (SD)>= 12 weeks, progressive disease (PD) or NE.
• Disease Control Rate (DCR) [ Time Frame: RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent ]
  Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) >= 12 weeks
• Duration of Response (DoR) [ Time Frame: RECIST tumour assessments were performed at screening (within 3 weeks before date of randomisation), then once every 12 weeks up to and including discontinuation of blinded study treatment, unless patients had withdrawn consent ]
  Response is defined as a confirmed best objective response of CR or PR. Duration of response is defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression (provided death is within 3 months of last RECIST assessment). Values are estimated as the medians weren't met
• Overall Survival (OS) [ Time Frame: Number of deaths since randomisation ]
  As data was immature at data cut off, number of death events is quoted
• Biochemical Response Calcitonin (CTN) [ Time Frame: Blood samples Blood samples for analysis of CTN were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up ]
  Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CTN.
• Biochemical Response Carcinoembryonic Antigen (CEA) [ Time Frame: Blood samples for analysis of CEA were taken at screening baseline (average of 0, 1, 4 and 8 hours), then every 4 weeks until discontinuation and 60 day follow up ]
  Best biochemical response was calculated from assessments at baseline and during treatment. Responders were those patients with a best biochemical response of CR or PR, confirmed by repeat assessments, which were to be performed no less than 4 weeks after the criteria for PR or CR were first met. CR and PR being defined according to level of CEA.
• Time to Worsening of Pain (TWP) [ Time Frame: During the last week of the screening period (Day -7 to Day 0), the brief pain inventory (BPI) and opioid analgesic use were self-reported once a day for 4 days to establish baseline, then every week during blinded study treatment, up to discontinuation. ]
  TWP was derived using the worst pain score from brief pain inventory (BPI) and patient reported opioid analgesic use. BPI uses 0 to 10 numeric rating scales asking subjects to rate their pain.

• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
• Official Title: An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer
• Brief Summary: The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Thyroid Cancer

Intervention

Drug: ZD6474 (Vandetanib)

once daily oral tablet

Other Names:

• ZACTIMA™
• SAR390530

Study Arms

• No Intervention: 1
  Placebo vandetanib
• Experimental: 2
  Vandetanib
  Intervention: Drug: ZD6474 (Vandetanib)

• Publications *: Wells SA Jr, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012 Jan 10;30(2):134-41. doi: 10.1200/JCO.2011.35.5040. Epub 2011 Oct 24. Erratum In: J Clin Oncol. 2013 Aug 20;31(24):3049.

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: April 1, 2014): 437
• Original Enrollment (submitted: December 12, 2006): 232
• Estimated Study Completion Date: June 28, 2024
• Actual Primary Completion Date: July 31, 2009 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.
• Presence of measurable tumor
• Able to swallow medication

Exclusion Criteria:

• Major surgery within 4 weeks before randomization
• Last dose of prior chemotherapy received less than 4 weeks prior to randomization
• Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
• Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
• Significant cardiac events
• Previous ZD6474 treatment

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switzerland, United States
• Removed Location Countries: Argentina, Bulgaria, China, Czech Republic, Former Serbia and Montenegro, United Kingdom

Administrative Information

• NCT Number: NCT00410761
• Other Study ID Numbers: D4200C00058; 2005-005077-29 ( EudraCT Number ); LPS14811 ( Other Identifier: Sanofi )
• Has Data Monitoring Committee: Not Provided
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Sanofi ( Genzyme, a Sanofi Company )
• Original Responsible Party: Not Provided
• Current Study Sponsor: Genzyme, a Sanofi Company
• Original Study Sponsor: AstraZeneca
• Collaborators: Not Provided

Investigators

• Study Director: Clinical Sciences & Operations; Sanofi

• PRS Account: Sanofi
• Verification Date: September 2023